Amneal announces bla submission of biosimilar candidate to xolair® (omalizumab)

Potential first-wave entry into the $4+ billion u.s. market and an important new growth driver for amneal potential first-wave entry into the $4+ billion u.s. market and an important new growth driver for amneal

AMRX Ratings Summary

AMRX Quant Ranking